Business Context and Reporting Period
This Form 8-K filing by AIKIDO PHARMA INC. (not Dominari Holdings Inc.) covers the Annual Meeting of Stockholders held on November 17, 2020. The company is a Delaware corporation with common stock trading on the Nasdaq Capital Market under the symbol AIKI.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It reports capital structure data as of September 24, 2020:
- Common Stock Outstanding: 34,920,219 shares
- Series D Convertible Preferred Stock: 4,725 shares
- Series D-1 Convertible Preferred Stock: 834 shares
- Meeting Attendance: Approximately 60% of total outstanding shares (21,074,252 shares represented)
Material Changes and Voting Results
Stockholders approved several governance and compensation proposals:
- Board Structure: Approved amending Bylaws to divide the Board into three classes (Class I, II, and III) with staggered terms expiring in 2021, 2022, and 2023.
- Director Elections: Elected Robert J. Vander Zanden and Tim S. Ledwick (Class I); Anthony Hayes and Robert Dudley (Class II); and Gregory James Blattner and Paul LeMire (Class III).
- Equity Plan: Approved increasing the 2014 Equity Incentive Plan share authorization from 243,344 to 5,000,000 shares.
- Accounting Firm: Ratified the appointment of Marcum LLP for the fiscal year ending December 31, 2020.
- Executive Compensation: Approved on a non-binding advisory basis.
Adjournment: The meeting was adjourned to December 4, 2020, to allow additional time for voting on Proposal 1, which sought authorization for a reverse stock split of up to one-for-ten.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future operations. The primary contingency noted is the pending vote on the reverse stock split, which the Board may abandon at its sole discretion. The adjournment indicates a need for further shareholder support to effect the split.
Investor Verification Checklist
- Verify the outcome of the adjourned meeting on December 4, 2020, regarding the reverse stock split proposal.
- Confirm the final composition of the Board of Directors following the election results.
- Review the impact of the increased equity plan authorization (5,000,000 shares) on potential future dilution.
- Check subsequent filings for the company's financial status, as this 8-K contains no financial performance data.